$1.76
-0.01 (-0.57%)
Open$1.73
Previous Close$1.77
Day High$1.82
Day Low$1.73
52W High$55.00
52W Low$1.71
Volume—
Avg Volume349.7K
Market Cap4.36M
P/E Ratio—
EPS$-107.92
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,471.6% upside
Current
$1.76
$1.76
Target
$27.66
$27.66
$20.34
$27.66 avg
$35.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.53M | 1.54M | 1.49M |
| Net Income | 146.8K | 155.5K | 142.3K |
| Profit Margin | 9.6% | 10.1% | 9.6% |
| EBITDA | 279.3K | 246.3K | 227.4K |
| Free Cash Flow | 124.0K | 159.2K | 163.1K |
| Rev Growth | +19.5% | +5.1% | +5.0% |
| Debt/Equity | 0.44 | 0.57 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |